Ryo Kameda, Kozo Okada, Masayasu Ikutomi, M. Brooke Hollak, Paul Yock, Jeffrey Popma, Sujith Seneviratne, Andrejs Erglis, Darren Walters, Robert Whitbourn, Jamie Layland, Jim Stewart, Seif El-Jack, Thomas Christen, Ian Meredith, Peter Fitzgerald and Yasuhiro Honda A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL Journal of the American College of Cardiology Volume 73, Issue 9 Supplement 1, March 2019 97(19)31718-8 DOI: 10.1016/S0735-10

Background

In second-generation bioresorbable scaffolds, thinner struts are often adopted to improve both deliverability and safety profiles, while theoretical concerns remain regarding radial strength and fracture resistance. This analysis aimed to evaluate acute and mid-term performance of the RENUVIA bioresorbable scaffold (thickness: 105 μm) using serial IVUS and OCT.